Revicki DA - Search Results

1

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.

Mirkin S, Graham S, Revicki DA, Bender RH, Bernick B, Constantine GD. Mirkin S, et al. Among authors: revicki da. Menopause. 2019 Jan 9;26(6):637-642. doi: 10.1097/GME.0000000000001294. Menopause. 2019. PMID: 30601452 Free PMC article. Clinical Trial.

2

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.

Constantine GD, Revicki DA, Kagan R, Simon JA, Graham S, Bernick B, Mirkin S. Constantine GD, et al. Among authors: revicki da. Menopause. 2019 May;26(5):513-519. doi: 10.1097/GME.0000000000001261. Menopause. 2019. PMID: 30516713 Free PMC article. Clinical Trial.

3

[No title available]

[No authors listed] [No authors listed] PMID: 32665531

4

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.

Constantine GD, Simon JA, Kaunitz AM, Pickar JH, Revicki DA, Graham S, Bernick B, Mirkin S. Constantine GD, et al. Among authors: revicki da. Menopause. 2020 Nov;27(11):1236-1241. doi: 10.1097/GME.0000000000001602. Menopause. 2020. PMID: 33110039 Free PMC article. Clinical Trial.

5

Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration.

Marshall RD, Collins A, Escolar ML, Jinnah HA, Klopstock T, Kruer MC, Videnovic A, Robichaux-Viehoever A, Burns C, Swett LL, Revicki DA, Bender RH, Lenderking WR. Marshall RD, et al. Among authors: revicki da. Orphanet J Rare Dis. 2019 Jul 12;14(1):174. doi: 10.1186/s13023-019-1142-1. Orphanet J Rare Dis. 2019. PMID: 31300018 Free PMC article.

6

A Scale to Assess Activities of Daily Living in Pantothenate Kinase-Associated Neurodegeneration.

Marshall RD, Collins A, Escolar ML, Jinnah HA, Klopstock T, Kruer MC, Videnovic A, Robichaux-Viehoever A, Swett L, Revicki DA, Bender RH, Lenderking WR. Marshall RD, et al. Among authors: revicki da. Mov Disord Clin Pract. 2019 Jan 22;6(2):139-149. doi: 10.1002/mdc3.12716. eCollection 2019 Feb. Mov Disord Clin Pract. 2019. PMID: 30838313 Free PMC article.

7

Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary.

Kawata AK, Hsieh R, Bender R, Shaffer S, Revicki DA, Bayliss M, Buse DC, Desai P, Sapra S, Ortmeier B, Hareendran A. Kawata AK, et al. Among authors: revicki da. Headache. 2017 Oct;57(9):1385-1398. doi: 10.1111/head.13162. Epub 2017 Aug 30. Headache. 2017. PMID: 28857154

8

Revicki DA, Sorensen S, Maton PN, Orlando RC. Revicki DA, et al. Dig Dis. 1998 Sep-Oct;16(5):284-91. doi: 10.1159/000016878. Dig Dis. 1998. PMID: 9892788 Clinical Trial.

9

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. Shikiar R, et al. Among authors: revicki da. Health Qual Life Outcomes. 2006 Sep 27;4:71. doi: 10.1186/1477-7525-4-71. Health Qual Life Outcomes. 2006. PMID: 17005043 Free PMC article. Clinical Trial.

10

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Revicki DA, et al. Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11. Dermatology. 2008. PMID: 18187944 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

392 results

Search Page